Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome

Leukemia

Volumn 20, Issue 3, 2006, Pages 410-416

  Stams, W A G ^a   Beverloo, H B ^b   den Boer, M L ^a   de Menezes, R X ^a,c   Stigter, R L ^a   van Drunen, E ^b   Ramakers van Woerden, N L ^d   Loonen, A H ^d   van Wering, E R ^e   Janka Schaub, G E ^f   Pieters, R ^a,e  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Childhood ALL; Clinical outcome; Drug resistance; Genetic abnormalities; TEL AML1

Indexed keywords

PREDNISOLONE; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 21; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; FOLLOW UP; GENE DELETION; HUMAN; IN VITRO STUDY; LEUKEMIA RELAPSE; LEUKOCYTE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

EID: 33644554828     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404083     Document Type: Article

References (43)

1. Hart SM, Foroni L. Core binding factor genes and human leukemia. Haematologica 2002; 87: 1307-1323.
2. Golub TR. TEL gene rearrangements in myeloid malignancy. Hematol Oncol Clin North Am 1997; 11: 1207-1220.
3. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252-4258.
4. Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J 1997; 16: 69-82.
5. Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv Cancer Res 1998; 75: 1-55.
6. Sawinska M, Ladon D. Mechanism, detection and clinical significance of the reciprocal translocation t(12;21)(p12;q22) in the children suffering from acute lymphoblastic leukaemia. Leuk Res 2004; 28: 35-42.
7. Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 1993; 13: 6336-6345.
8. Loh ML, Rubnitz JE. TEL/AML1-positive pediatric leukemia: Prognostic significance and therapeutic approaches. Curr Opin Hematol 2002; 9: 345-352.
9. Ramakers-van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000; 96: 1094-1099.
10. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, Stigter RL, van Wering ER et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood 2003; 101: 2743-2747.
11. Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: Two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996; 87: 2891-2899.
12. Cave H, Cacheux V, Raynaud S, Brunie G, Bakkus M, Cochaux P et al. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. Leukemia 1997; 11: 1459-1464.
13. Fears S, Vignon C, Bohlander SK, Smith S, Rowley JD, Nucifora G. Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 1996; 17: 127-135.
14. Kobayashi H, Satake N, Maseki N, Sakashita A, Kaneko Y. The der(21)t(12;21) chromosome is always formed in a 12;21 translocation associated with childhood acute lymphoblastic leukaemia. Br J Haematol 1996; 94: 105-111.
15. Andreasson P, Johansson B, Strombeck B, Donner M, Mitelman F, Hoglund M. Childhood acute lymphoblastic leukaemia with ider(21)(q10)t(12;21)(p12;q22): A new recurrent abnormality showing ETV6/ CBFA2 fusion. Br J Haematol 1997; 98: 216-218.
16. Loncarevic IF, Roitzheim B, Ritterbach J, Viehmann S, Borkhardt A, Lampert F et al. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. Genes Chromosomes Cancer 1999; 24: 272-277.
17. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolonevincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268.
18. Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers GJ, Van der Plas D et al. Translocation of BCR to chromosome 9: A new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia. Genes Chromosomes Cancer 1993; 8: 237-245.
19. Sacchi N, Nisson PE, Watkins PC, Faustinella F, Wijsman J, Hagemeijer A. AML1 fusion transcripts in t(3;21) positive leukemia: Evidence of molecular heterogeneity and usage of splicing sites frequently involved in the generation of normal AML1 transcripts. Genes Chromosomes Cancer 1994; 11: 226-236.
20. Wlodarska I, Baens M, Peeters P, Aerssens J, Mecucci C, Brock P et al. Biallelic alterations of both ETV6 and CDKN1B genes in a t(12;21) childhood acute lymphoblastic leukemia case. Cancer Res 1996; 56: 2655-2661.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
23. Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson R, Nachman JB et al. Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. Cancer 2000; 88: 1945-1954.
24. Raimondi SC, Shurtleff SA, Downing JR, Rubnitz J, Mathew S, Hancock M et al. 12p abnormalities and the TEL gene (ETV6) in childhood acute lymphoblastic leukemia. Blood 1997; 90: 4559-4566.
25. Attarbaschi A, Mann G, Konig M, Dworzak MN, Trebo MM, Muhlegger N et al. Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: An interphase FISH analysis. Leukemia 2004; 18: 1611-1616.
26. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723-2729.
27. Takahashi Y, Horibe K, Kiyoi H, Miyashita Y, Fukuda M, Mori H et al. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998; 20: 190-195.
28. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002; 16: 1099-1111.
29. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239.
30. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-417.
31. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999; 354: 1499-1503.
32. McHale CM, Wiemels JL, Zhang L, Ma X, Buffler PA, Guo W et al. Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California. Genes Chromosomes Cancer 2003; 37: 36-43.
33. Konrad M, Metzler M, Panzer S, Ostreicher I, Peham M, Repp R et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: Evidence for the persistence of a preleukemic clone. Blood 2003; 101: 3635-3640.
34. Pine SR, Wiemels JL, Jayabose S, Sandoval C. TEL-AML1 fusion precedes differentiation to pre-B cells in childhood acute lymphoblastic leukemia. Leuk Res 2003; 27: 155-164.
35. Ford AM, Fasching K, Panzer-Grumayer ER, Koenig M, Haas OA, Greaves MF. Origins of 'late' relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood 2001; 98: 558-564.
36. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer 1999; 35: 173-185.
37. Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002; 99: 8242-8247. Epub 2002 Jun 4.
38. Andreasson P, Schwaller J, Anastasiadou E, Aster J, Gilliland DG. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet 2001; 130: 93-104.
39. Bernardin F, Yang Y, Cleaves R, Zahurak M, Cheng L, Civin CI et al. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res 2002; 62: 3904-3908.
40. Fenrick R, Amann JM, Lutterbach B, Wang L, Westendorf JJ, Downing JR et al. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol 1999; 19: 6566-6574.
41. Guidez F, Petrie K, Ford AM, Lu H, Bennett CA, MacGregor A et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 2000; 96: 2557-2561.
42. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A et al. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996; 16: 1349-1355.
43. Poirel H, Oury C, Carron C, Duprez E, Laabi Y, Tsapis A et al. The TEL gene products: Nuclear phosphoproteins with DNA binding properties. Oncogene 1997; 14: 349-357.